Bicycle Therapeutics PLC (BCYC) stock
BCYCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 11/3080% below fair value
$3.18−0.19 (-5.64%)
Close on Nov 16, 2026Market cap $222.90MP/E –Yield 0.00%
Bicycle Therapeutics cash
Cash and short-term investments held at the end of each period.
Bicycle Therapeutics's cash was $469.93M at Sep 30, 2026. For fiscal 2025 it was $628.11M, down 28.6% from the year before. The highest annual figure on record is $880.07M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $628.11M | -28.6% |
| FY2024 | Dec 31, 2024 | $880.07M | +67.2% |
| FY2023 | Dec 31, 2023 | $526.42M | +55.2% |
| FY2022 | Dec 31, 2022 | $339.15M | -22.7% |
| FY2021 | Dec 31, 2021 | $438.68M | +222.6% |
| FY2020 | Dec 31, 2020 | $135.99M | +47.6% |
| FY2019 | Dec 31, 2019 | $92.12M | +45.3% |
| FY2018 | Dec 31, 2018 | $63.38M | -6.3% |
| FY2017 | Dec 31, 2017 | $67.66M | +619.7% |
| FY2016 | Dec 31, 2016 | $9.40M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $469.93M | -27.5% |
| Q2 FY2026 | Jun 30, 2026 | $510.05M | -29.3% |
| Q1 FY2026 | Mar 31, 2026 | $559.47M | -29.4% |
| Q4 FY2025 | Dec 31, 2025 | $628.11M | -28.6% |
| Q3 FY2025 | Sep 30, 2025 | $648.33M | -27.2% |
| Q2 FY2025 | Jun 30, 2025 | $721.45M | -25.0% |
| Q1 FY2025 | Mar 31, 2025 | $792.97M | +73.5% |
| Q4 FY2024 | Dec 31, 2024 | $880.07M | +67.2% |
| Q3 FY2024 | Sep 30, 2024 | $890.86M | +55.7% |
| Q2 FY2024 | Jun 30, 2024 | $961.36M | +182.4% |
| Q1 FY2024 | Mar 31, 2024 | $457.00M | +55.5% |
| Q4 FY2023 | Dec 31, 2023 | $526.42M | +55.2% |
| Q3 FY2023 | Sep 30, 2023 | $572.09M | +58.3% |
| Q2 FY2023 | Jun 30, 2023 | $340.43M | -8.7% |
| Q1 FY2023 | Mar 31, 2023 | $293.82M | -27.9% |
| Q4 FY2022 | Dec 31, 2022 | $339.15M | -22.7% |
| Q3 FY2022 | Sep 30, 2022 | $361.47M | +39.3% |
| Q2 FY2022 | Jun 30, 2022 | $372.77M | +87.6% |
| Q1 FY2022 | Mar 31, 2022 | $407.37M | +107.9% |
| Q4 FY2021 | Dec 31, 2021 | $438.68M | +222.6% |
| Q3 FY2021 | Sep 30, 2021 | $259.52M | +73.2% |
| Q2 FY2021 | Jun 30, 2021 | $198.74M | +105.1% |
| Q1 FY2021 | Mar 31, 2021 | $195.90M | +78.7% |
| Q4 FY2020 | Dec 31, 2020 | $135.99M | +47.6% |
| Q3 FY2020 | Sep 30, 2020 | $149.84M | +56.2% |
| Q2 FY2020 | Jun 30, 2020 | $96.91M | -10.7% |
| Q1 FY2020 | Mar 31, 2020 | $109.64M | +84.7% |
| Q4 FY2019 | Dec 31, 2019 | $92.12M | +45.3% |
| Q3 FY2019 | Sep 30, 2019 | $95.95M | +100.2% |
| Q2 FY2019 | Jun 30, 2019 | $108.54M | +103.2% |
| Q1 FY2019 | Mar 31, 2019 | $59.36M | -12.3% |
| Q4 FY2018 | Dec 31, 2018 | $63.38M | +574.1% |
| Q3 FY2018 | Sep 30, 2018 | $47.92M | – |
| Q2 FY2018 | Jun 30, 2018 | $53.40M | – |
| Q4 FY2017 | Dec 31, 2017 | $67.66M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.40M | – |
See a number that looks wrong?